Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Raises $6.7M

NEW YORK (GenomeWeb News) – Epigenomics today said that it raised almost €5 million ($6.7 million) in a successful completion of a capital increase.

The increase was achieved through a rights issue and a subsequent private placement. As a result of the capital increase, Epigenomics said its cash runway has been extended to at least the fourth quarter of 2013.

The company announced the raise in December. As of Sept. 30, 2012, it reported having €5.7 million in cash and cash equivalents.

Epigenomics added that it continues exploring all strategic options for the firm, including securing other financial resources to support its operations. A few weeks ago, it said that it had completed its submission to the US Food and Drug Administration for premarket approval of its Epi proColon blood-based test for the detection of colorectal cancer.

Epigenomics is based in Berlin and has offices in Seattle.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.